The aim of this Research Training Program is to recruit and prepare highly qualified physician/scientists for an academic research career in medical or gynecological oncology by developing research skills in cancer biology and therapy. The general areas of training include: 1) Clinical Hematopoietic Cell Transplantation;2) Immunology and Vaccine Development;3) Transplantation Biology;4) Stem/Progenitor Cell Biology;5) Women's Cancer Research;6) Genito-urinary Cancer Research;7) Gastro-intestinal Cancer Research;8) Human Biology. All trainees will be members of the Hematology/Oncology or Gynecologic Oncology Fellowship Programs of the University of Washington/Fred Hutchinson Cancer Research Center. Trainees receive specific didactic training in the fundamentals of oncology research, including biostatistics, protocol development, data analysis, medical and research ethics, use and care of animals in research and use of human subjects in research. The majority of the trainee's time is spent conducting research under the direct supervision of a faculty mentor selected by the trainee with additional guidance from the Fellowship Training Program Committee.

Public Health Relevance

In 2009, approximately 1.48 million individuals in the United States will be diagnosed with cancer and 563,000 will die of the disease. Clearly, new approaches to cancer prevention, diagnosis and treatment are needed, and these will only come from new insights achieved through research. This Research Training Program is designed to directly respond to this need by recruiting and training exceptionally qualified physician scientists for a career in cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009515-29
Application #
8517441
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1985-07-01
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
29
Fiscal Year
2013
Total Cost
$638,503
Indirect Cost
$47,738
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Cowan, Andrew J; Stevenson, Philip A; Cassaday, Ryan D et al. (2016) Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant 22:380-5
Cohen, Stacey A; Laurino, Mercy; Bowen, Deborah J et al. (2016) Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. Cancer 122:393-401
Philip, Mary; Chiu, Edison Y; Hajjar, Adeline M et al. (2016) TLR Stimulation Dynamically Regulates Heme and Iron Export Gene Expression in Macrophages. J Immunol Res 2016:4039038
Kocarnik, Jonathan M; Shiovitz, Stacey; Phipps, Amanda I (2015) Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 3:269-76
Shiovitz, S; Korde, L A (2015) Genetics of breast cancer: a topic in evolution. Ann Oncol 26:1291-9
Yu, Miao Crystal; Austin, R Marshall; Lin, Jeff et al. (2015) The Role of High-Risk Human Papilloma Virus Testing in the Surveillance of Cervical Cancer After Treatment. Arch Pathol Lab Med 139:1437-40
Woo, Janghee; Cohen, Stacey A; Grim, Jonathan E (2015) Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) 3:316-29
Stanton, Sasha E; Ward, Maureen M; Christos, Paul et al. (2015) Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer 15:267
Cho, Eunpi; Mostaghel, Elahe A; Russell, Kenneth J et al. (2015) In Reply to Bhattacharyya et al. Int J Radiat Oncol Biol Phys 93:719-20
Cowan, Andrew J; Frayo, Shani L; Press, Oliver W et al. (2015) Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Anticancer Drugs 26:974-83

Showing the most recent 10 out of 154 publications